
https://www.science.org/content/blog-post/sticking-together-solution
# Sticking Together in Solution (December 2019)

## 1. SUMMARY

The article discusses the persistent challenge of poor aqueous solubility in small-molecule drug development, noting that medicinal chemistry's default reliance on hydrophobic binding interactions naturally leads to "brick dust" compounds that formulation teams must struggle to deliver. It highlights the empirical, often frustrating nature of solubility enhancement techniques and the growing problem posed by larger molecules like protein-protein interaction inhibitors and bifunctional degraders.

The piece focuses on a 2019 JACS paper from Hebrew University studying caffeine's aggregation behavior in water and the differential effects of hydrotropes—particularly how sugars like glucose and sucrose actually decrease caffeine's *overall* solubility but stabilize caffeine *monomers* by preferentially interacting with the ends of caffeine oligomer stacks. The work identifies trehalose as an outlier with enhanced exclusion from oligomer surfaces, introducing the concept of "selective hydrotropy" and raising the prospect of rationally designing excipients that stabilize drug monomers while disrupting problematic aggregates.

## 2. HISTORY

Following the article's publication, several developments occurred in drug formulation strategies and our understanding of solubility challenges:

**Actual drug approvals and clinical outcomes:**
- Many drug candidates continued to face formulation hurdles due to poor solubility, particularly as molecular weights increased. PROTACs and protein-protein interaction inhibitors that emerged around this period indeed struggled with bioavailability.
- The shift toward larger molecules did materialize as predicted, with drugs like Venetoclax (approved 2016, but expanded use post-2019) requiring specialized formulations.
- Several biologics and larger molecules approved post-2019 rely on advanced delivery systems, though many successful CNS drugs remain surprisingly simple small molecules.

**Scientific methodology developments:**
- No major breakthrough in predictive hydrotropy design emerged that I can confidently report. Selective hydrotropy remains a niche academic concept.
- Formulation science continued relying heavily on empirical approaches, with lipid-based formulations, amorphous solid dispersions, and nanoparticle approaches dominating practical solutions.
- Computational methods improved for predicting crystallization tendencies and aggregation, but rational excipient design remains challenging.

**Industry adoption:**
- The basic formulation toolkit expanded incrementally rather than through revolutionary new excipients. Trehalose gained wider use as a stabilizer, particularly in biologics and vaccines, but not primarily for the selective mechanism described.
- COVID-19 vaccine development (2020-2021) accelerated interest in stabilization strategies, with mRNA vaccines using lipid nanoparticles rather than classical solubility enhancers.

**Public policy and regulation:**
- FDA and EMA guidance documents on quality-by-design for formulations evolved, but no major regulatory shifts specific to hydrotropy occurred that I can confidently state.

## 3. PREDICTIONS

The article made several implicit and explicit predictions:

• **"Is it going to be mostly trehalose or are there more things waiting out there to be found?"**
  - **Outcome**: Trehalose adoption did increase, but primarily in biologics stabilization and vaccine formulations rather than small-molecule selective hydrotropy. No major new selective hydrotropes entered widespread commercial use based on the mechanism described. The concept remained academically interesting but didn't translate to routine formulation practice.

• **Implicit prediction that the trend toward larger molecules (protein-protein interaction inhibitors, bifunctional degraders) would exacerbate solubility problems**
  - **Outcome**: **Accurate**. PROTACs, molecular glues, and PPI inhibitors did indeed face severe formulation challenges. Many required complex delivery strategies, and some struggled with oral bioavailability, forcing IV administration or abandonment.

• **Implicit prediction that understanding selective stabilization mechanisms would lead to rational design of better formulations**
  - **Outcome**: **Partially incorrect**. While understanding advanced, rational design based on differential oligomer interaction never became mainstream. The field continued relying on traditional empirical approaches combined with lipid-based and nanoparticle systems.

• **Implicit concern that aggregation-related bioavailability issues would intensify**
  - **Outcome**: **Accurate**. Studies of amorphous solid dispersions and polymers increasingly recognized the importance of maintaining supersaturation and preventing nucleation. The mechanisms discussed (differential oligomer stability) remained relevant even if the specific solution proposed didn't revolutionize practice.

## 4. INTEREST

Rating: **5/10**

The article addresses a genuine, persistent problem in pharmaceutical science and highlights an intellectually interesting but ultimately niche academic finding. While dissolution and bioavailability challenges have remained crucial in drug development, the specific mechanism of selective hydrotropy and differential oligomer stabilization never translated into major practical advances or regulatory-impacting formulation strategies. The broader discussion of formulation challenges has aged well, but the specific scientific advance proved less consequential than might have been hoped.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20191212-sticking-together-solution.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_